-
Approximately half of all cases of heart failure occur in the context of normal systolic function (heart failure with preserved ejection fraction [HFPEF]) and the number of cases is projected to rise as the population ages.
-
In severe symptomatic aortic stenosis (AS), surgical AVR improves mortality, but there is no medical therapy proven to slow progression of the valvular stenosis.
-
In this study, Siklody and her colleagues from three large and experienced atrial fibrillation (AF) ablation centers performed cerebral magnetic resonance imaging before and after AF ablation using three different catheter technologies.
-
This report is from the ARISTOTLE trial, which was just reported at the recent European Society of Cardiology meeting in Paris. Apixaban is a new direct oral factor Xa inhibitor with a favorable pharmacokinetic profile.
-
-
Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.
-
New emphasis on optimal medical therapy in atherosclerotic cardiovascular (CV) disease has focused attention on the short-term variability of blood pressure (BP) measurements and the difficulty this poses for the diagnosis and treatment of hypertension.
-
This paper presents data from the Nurses' Health Study. This is a large study that was begun in 1976 which surveyed nurses with initial ages between 30 and 55 and collected data on lifestyle and other risk factors and correlated these data with the development of cardiac disease.
-
In this paper, the authors present data from the Valsartan in Acute Myocardial Infarction Trial (VALIANT) on the circumstances and outcomes of cardiac arrest after myocardial infarction (MI).
-
Percutaneous transcatheter aortic valve implantation (TAVI) is an emerging technique for the treatment of aortic stenosis (AS). By this method, a bioprosthetic valve (bovine pericardium) attached to a stent can be deployed in the aortic valve position via a catheter delivery system inserted through either the femoral artery or via the apex of the left ventricle. This technique is available in Europe and is being considered by the FDA for release in the United States.
